From: A Canadian naturalistic study of a community-based cohort treated for bipolar disorder
Single SGA Received | LS Mean for Change from Baseline to One Year with Propensity Adjustment | 95% Confidence Interval | Pvalue* |
---|---|---|---|
YMRS | Â | Â | Â |
olanzapine (n = 154) | -15.9 | -16.7 to -15.2 | 0.835 |
risperidone (n = 41) | -15.9 | -17.3 to -14.5 | Â |
quetiapine (n = 38) | -15.5 | -16.9 to -14.1 | Â |
MADRS | Â | Â | Â |
olanzapine (n = 154) | -7.5 | -8.8 to -6.2 | 0.552 |
risperidone (n = 42) | -6.2 | -8.7 to -3.7 | Â |
quetiapine (n = 37) | -7.8 | -10.4 to -5.3 | Â |
BAI | Â | Â | Â |
olanzapine (n = 132) | -7.0 | -8.4 to -5.6 | 0.935 |
risperidone (n = 34) | -6.9 | -9.7 to -4.1 | Â |
quetiapine (n = 32) | -6.4 | -9.4 to -3.5 | Â |
SF-12 Mental Composite | Â | Â | Â |
olanzapine (n = 127) | 6.3 | 4.0 to 8.7 | Â |
risperidone (n = 37) | 5.0 | 0.5 to 9.5 | 0.057 |
quetiapine (n = 31) | 11.9 | 7.1 to 16.8 | Â |
SF-12 Physical Composite | Â | Â | Â |
olanzapine (n = 127) | 0.6 | -1.4 to 2.5 | 0.077 |
risperidone (n = 37) | -0.7 | -4.4 to 3.0 | Â |
quetiapine (n = 31) | -4.4 | -8.4 to -0.5 | Â |